Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:34:06 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:MNKD - MANNKIND CORPORATION - https://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q0.13.08·3.600.23.390.52    6.51  2.2305:21:11Jun 0515 min RT 2¢

Recent Trades - All 2 today
Time ETExPriceChangeVolume
05:21:11Q3.3791-0.01091
04:00:13Q3.36-0.032
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-05 19:35U:MNKDNews ReleaseData at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind's Afrezza(TM) (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
2026-06-03 06:05U:MNKDNews ReleaseMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
2026-05-29 14:00U:MNKDNews ReleaseMannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
2026-05-29 12:30U:MNKDNews ReleaseMannKind Announces FDA Approval of Afrezza(TM), the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
2026-05-27 16:00U:MNKDNews ReleaseMannKind to Present at Jefferies Global Healthcare Conference
2026-05-27 09:05U:MNKDNews ReleaseMannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza(TM)) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
2026-05-06 16:01U:MNKDNews ReleaseMannKind Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 06:30U:MNKDNews ReleaseMannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
2026-04-29 16:01U:MNKDNews ReleaseMannKind to Report First Quarter 2026 Financial Results on May 6, 2026
2026-03-09 09:05U:MNKDNews ReleaseMannKind to Present New Data From Pediatric and Adult Studies of Afrezza(TM) at ATTD 2026
2026-03-05 16:30U:MNKDNews ReleaseMannKind Announces Settlement of Convertible Senior Notes
2026-03-04 09:00U:MNKDNews ReleaseMannKind to Participate in Upcoming Investor Conferences
2026-02-26 08:00U:MNKDNews ReleaseMannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-19 09:00U:MNKDNews ReleaseMannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-02-18 09:00U:MNKDNews ReleaseMannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2026-02-09 06:05U:MNKDNews ReleaseMannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza(TM) for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
2026-01-26 06:05U:MNKDNews ReleaseMannKind Announces FDA Approval of Updated Afrezza(TM) Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
2026-01-23 12:56U:MNKDNews ReleaseBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
2026-01-08 08:05U:MNKDNews ReleaseMannKind Provides Business Updates and 2026 Growth Drivers
2025-12-23 08:05U:MNKDNews ReleaseMannKind Shares FUROSCIX(TM) Business Updates